GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (LSE:POLB) » Definitions » Cash Flow from Others

Poolbeg Pharma (LSE:POLB) Cash Flow from Others : £0.27 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Cash Flow from Others?

Poolbeg Pharma's cash flow from others for the six months ended in Jun. 2024 was £0.18 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2024 was £0.27 Mil.


Poolbeg Pharma Cash Flow from Others Historical Data

The historical data trend for Poolbeg Pharma's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Cash Flow from Others Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Others
- -0.12 -0.18

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Others Get a 7-Day Free Trial -0.04 -0.07 -0.27 0.09 0.18

Poolbeg Pharma Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.27 Mil.

Poolbeg Pharma Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines